BMS and Prime ink potential $3.5bn deal to develop T cell therapies
Pharmaceutical Technology
OCTOBER 1, 2024
As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.
New Corona test developed
Scienmag
MARCH 5, 2021
Researchers develop a low-cost and fast method to detect a COVID-19 infection from a pool of gargle lavage samples Credit: MPI f. However, it requires expensive laboratory equipment and global shortages of reagents […]. However, it requires expensive laboratory equipment and global shortages of reagents […].
Development 
94
94 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sartorius upscales gene therapy prowess with $2.6bn Polyplus acquisition
Pharmaceutical Technology
APRIL 3, 2023
The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus’s technologies will be a complementary addition to Satorius’s cell culture media and development of gene therapeutics.
Gene Therapy 246
246 
New COVID test doesn’t use scarce reagents, catches all but the least infectious
Scienmag
OCTOBER 2, 2020
Addresses major testing need in developing world; also in US, where reagent supplies are again dwindling Credit: Brian Jenkins A major roadblock to large scale testing for coronavirus infection in the developing world is a shortage of key chemicals, or reagents, needed for the test, specifically the ones used to extract the virus’s genetic material, (..)
Reagent 52
52 
Modernizing cell culture processes for the next wave of genomic medicine
Pharmaceutical Technology
FEBRUARY 3, 2023
With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. So, we set out to solve some of the problems,” she explains.
Genome 244
244 
Mastering Ultra-Low Freezer Repair: A Comprehensive Guide
Pharma Mirror
FEBRUARY 14, 2024
In the dynamic realm of laboratory instruments, ultra-low freezers play a pivotal role in preserving valuable samples and reagents. These sophisticated devices are crucial for various fields, ranging from medical research to pharmaceutical development.
Reagent 130
130 
MIP Discovery raises £7m to drive commercialization in cell and gene space
BioPharma Reporter
FEBRUARY 22, 2024
MIP Discovery, a developer of non-biological affinity reagents designed to accelerate the production of cell and gene therapies, has closed a Â7 million Series A financing round, led by Mercia Ventures.
Gene 93
93 
Using analytics and bioassays to de-risk your mRNA LNP drug development programme
Pharmaceutical Technology
FEBRUARY 15, 2023
The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. The bioassays are the canary in the coal mine of how well your process development is going.
Bioassay 130
130 
SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
BioTech 365
OCTOBER 5, 2021
SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio Rapid development of key mutation detection reagents continues to facilitate critical investigation and monitoring activities SYDNEY–(BUSINESS WIRE)–#COVID19–SpeeDx Pty.
Genotype 40
40 
Avacta Ships SARS-COV-2 Affimer Reagents to Cytiva and Adeptrix
Drug Discovery Today
MAY 13, 2020
Cambridge and Wetherby, UK, 11 May 2020: Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners.
Reagent 40
40 
Considerations for Mobile Health Technology Developers: Part 1
pharmaphorum
SEPTEMBER 29, 2022
Although mHealth has been gaining in popularity for at least the past decade, before commercializing their mHealth products, developers must determine whether the product is subject to U.S. If so, developers must develop and execute on a regulatory strategy. Food and Drug Administration (FDA) regulation as a medical device.
Development 104
104 
Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research
BioTech 365
JANUARY 6, 2021
Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research Adeptrix Closes Series A Financing to Commercialize BAMS™ Bioanalytical Reagents for Life Science Research BEVERLY, Mass.–(BUSINESS
Reagent 40
40 
Monkeypox Test Kit in Development by Becton Dickinson in Partnership with CerTest Biotec
XTalks
JUNE 27, 2022
Leading global medical technology company Becton Dickinson (BD) and Spain’s CerTest Biotec have announced they will be collaborating to develop a molecular diagnostic test for the detection of the monkeypox virus. However, he said the global health agency is closely monitoring the evolving situation.
Development 83
83 
Scientists propose potential method for imaging-guided synergistic cancer therapy
Scienmag
OCTOBER 15, 2020
LIN Wenchu from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science developed a synthesis of metal-free multifunctional therapeutic reagents, called graphitic carbon nitride quantum dots embedded in carbon nanosheets (CNQD-CN), via a one-step hydrothermal treatment. WANG Hui and Prof.
Reagent 85
85 
STAT+: Up and down the ladder: The latest comings and goings
STAT News
AUGUST 26, 2022
This time around, we note that Ansa Biotechnologies hired Jeremiah Hanes as senior vice president, research and development. Previously, he worked at PacBio, where he was most recently vice president, reagents R&D. And here is our regular feature in which we highlight a different person each week.
Reagent 98
98 
Top 30 New Medical Devices of 2024
XTalks
JANUARY 21, 2025
TriClip G4 System Manufacturer/developer : Abbott Medical Date of FDA approval : April 1, 2024 Approved for : Tricuspid regurgitation (TR). Abbott Spinal Cord Stimulation (SCS) Systems Manufacturer/developer : Abbott Medical Date of FDA approval : May 30, 2024 Approved for : Chronic, hard-to-manage pain in the torso, arms and legs.
FDA Approval 105
105 
The ABCs of Transitioning PK Assays from Preclinical to Clinical
Worldwide Clinical Trials
SEPTEMBER 29, 2022
a typical format is: receptor/target as capture with a generic binding reagent as detection (e.g., If so, it’s important to plan for development of this assay as within the project timeline. For studies of humanized therapeutics (monoclonal antibodies [mAb], fusion protein, antibody-drug conjugates [ADC], bispecific antibodies, etc.),
Reagent 130
130 
UK’s Salient Bio launches robotic COVID-19 testing platform
pharmaphorum
NOVEMBER 26, 2020
The platform is reagent agnostic, meaning that disruption in supply chains can be mitigated by a shift to different reagent suppliers without it calling for wholesale infrastructure change at Salient’s labs, therefore limiting disruption and costs.
Reagent 93
93 
FDA INTERACT Meetings: Early Interactions for Cell and Gene Therapy Sponsors
Camargo
MAY 2, 2021
Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Source: Medicines in Development | 2020 Update: Cell and Gene Therapy , PhRMA.
Gene Therapy 155
155 
Swittons Introduces Smart IoT Devices for Pharmaceutical Lab Digital Transformation Initiatives
pharmaphorum
AUGUST 16, 2020
There are profound changes taking place in the area of life science research and development,” stated Swittons CEO and Founder Anupam Nandwana. Reorder reagents. Swittons is powered by the technology and expertise developed by P360. Notify of spill/cleaning needed. Equipment occupancy notification. Re-stock disposable supplies.
Life Science 129
129 
Key Trends in Non-Viral Transfection Market
Roots Analysis
APRIL 5, 2023
In fact, non-viral vectors are significantly less expensive than their virus-based counterparts, implying the potential for use in the development of more affordable gene therapies. Currently, highest number of patent for non-viral transfection reagents and systems is filed in North America region.
Reagent 52
52 
Niche Nonclinical Studies: Uncommon Routes of Administration and Animal Models
Camargo
JUNE 9, 2021
We have collaborated with sponsors on many niche programs that have shone a light on both the creativity and the broad range of specialized capabilities needed for such complex development programs. Niche Nonclinical Routes of Administrations. However, there are numerous less common options, including hamster, guinea pig, ferret, and lamb.
Reagent 178
178 
Donaldson acquires Isolere Bio
BioPharma Reporter
FEBRUARY 21, 2023
Donaldson Company will acquire Isolere Bio: an early-stage biotech that develops novel and proprietary âIsoTagâ reagents and accompanying filtration processes used for the purification and streamlined manufacturing of biopharmaceuticals.
Reagent 52
52 
DNA Cloning Market: A Step Towards Future of Genetics Science
Roots Analysis
JUNE 1, 2022
The pandemic has specifically resulted in enhanced research and development activities in the field of biotechnology. Recent technological advancements have led to development of novel DNA cloning kits and reagents, which are cost-effective, faster and more efficient than conventional methods. DNA Cloning Reagents Market.
DNA 52
52 
OTAT Town Hall on Cell Therapy CMC – The Recording is Available but Here’s an Appetizer
FDA Law Blog
JANUARY 4, 2023
The purpose of these town halls are to discuss topics related to OTAT-regulated products, engage with product development stakeholders, and to provide information to help stakeholders to help advance drug development. The next town hall will focus on the clinical development of gene therapy products for rare diseases in February 2023.
Reagent 59
59 
Leading API biologics (protein and peptide) companies in contract marketing
Pharmaceutical Technology
SEPTEMBER 14, 2022
Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development. Technologies in the delivery of peptides and proteins.
Protein 100
100 
A new era in diagnostics: The growing demand for POC testing
Pharmaceutical Technology
SEPTEMBER 1, 2022
In the pursuit of improving patient care, the continued development of POC testing can help support future demand for rapid diagnosis and treatment, with opportunities to implement successful POC facilities expanding over the years as the technology has improved. To compose one full molecular device, there are many, many components.”. “The
Manufacturing 130
130 
Vivlion GmbH Signs Worldwide License Agreement With ERS Genomics for CRISPR/Cas9 Patent Portfolio
The Pharma Data
NOVEMBER 30, 2020
The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. The license from ERS Genomics now enables Vivlion to offer both R&D reagents and screening services to its customers worldwide. CEO of Vivlion.
Genome 52
52 
Assay Development Scientist Jobs: What to Know About the Field
XTalks
OCTOBER 19, 2023
An assay development scientist combines deep biological and biochemical expertise with practical laboratory skills to develop tests that can answer specific biological questions or drive the drug discovery process. Related: Pharmaceutical Scientist Jobs: What to Know Before Applying What Does an Assay Development Scientist Do?
Scientist 59
59 
IN FOCUS: Syngene International
Pharmaceutical Technology
APRIL 28, 2023
The company has been ranked in the Business Expansion and Research and Development categories in the Pharmaceutical Technology Excellence Rankings. Initially centered on Librela®, this agreement paves the way for developing and manufacturing other molecules in the coming years. until 2026. until 2026.
Manufacturing 130
130 
Healthy.io’s Smartphone-Powered Minuteful Kidney Test Gets FDA Clearance
XTalks
JULY 13, 2022
Around one in three adults in the US (or about 80 million Americans) are at risk of developing CKD. An ACR urine reagent dipstick/strip. An absorbent pad to remove excess liquid from the reagent strip. The reagent strip is dipped into the urine sample for one second and any excess liquid is removed using the absorbent pad.
Reagent 98
98 
Euro Convergence: Academic clinics should establish risk management programs for ATMP development
The Pharma Data
MAY 17, 2021
Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Uharek is a hematologist and cell and gene therapy specialist at Berlin’s Charité Hospital. .
Development 52
52 
Yale-NBA Partnership Results in FDA Approval for COVID-19 SalivaDirect Test
XTalks
AUGUST 18, 2020
The test has been developed by researchers at the Yale School of Public Health and is being touted as a game changer for fast and easy COVID testing. Having a test that requires less reagents and resources, such as the RNA extraction kits, increases capabilities for increased testing. We are not developers of diagnostics.
FDA Approval 90
90 
Invivoscribe Appoints Loui Madakamutil to Lead Its Therapeutics Division as Chief Scientific Officer
BioTech 365
SEPTEMBER 8, 2020
an industry pioneer in developing and commercializing diagnostic products and reagents for hematological malignancies, announced today key members of the leadership team hired to direct Invivoscribe Therapeutics, Inc., its fully integrated drug development engine. Invivoscribe Therapeutics … Continue reading →
Reagent 40
40 Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner
BioTech 365
AUGUST 6, 2020
Avacta appoints BBI Solutions as manufacturing partner for the rapid SARS-CoV-2 antigen test being developed with Cytiva CAMBRIDGE, England & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it … Continue reading →
Cell Therapy Consumables Industry: Current Scenario and Future Trends
Roots Analysis
AUGUST 29, 2023
Raw materials used for the production of cell therapies include culture media, growth factors, extracellular matrices and reagents. During the development of these therapies, raw material changes can be expected and the impact of these modifications on the final product must be assessed.
Reagent 52
52 
Teknova to Join the Nasdaq Biotechnology Index
BioTech 365
DECEMBER 15, 2021
Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of … Continue reading → Teknova to Join the Nasdaq Biotechnology Index Teknova to Join the Nasdaq Biotechnology Index HOLLISTER, Calif., 15, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc.
Reagent 40
40 
Teknova to Participate in Upcoming Investor Conferences
BioTech 365
NOVEMBER 16, 2021
Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of … Continue reading → Teknova to Participate in Upcoming Investor Conferences Teknova to Participate in Upcoming Investor Conferences HOLLISTER, Calif., 16, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc.
Reagent 40
40 
Avacta to Launch SARS-CoV-2 ELISA Laboratory Test
BioTech 365
SEPTEMBER 7, 2020
Avacta to make a high performance Affimer research ELISA test available to support global research efforts to combat the coronavirus CAMBRIDGE & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce … Continue reading →
Reagent 40
40 
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement
BioTech 365
FEBRUARY 23, 2021
ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement ERS Genomics and G+FLAS Life Sciences sign CRISPR/Cas9 license agreement G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents DUBLIN & SEOUL–(BUSINESS WIRE)–ERS Genomics Limited, which … Continue reading →
Life Science 40
40 Avacta Expands Rapid SARS-CoV-2 Antigen Test Manufacturing Capacity
BioTech 365
SEPTEMBER 2, 2020
Manufacturing agreement with Abingdon Health for Avacta’s rapid COVID-19 saliva test WETHERBY & CAMBRIDGE, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it has entered into an agreement with Abingdon … Continue reading → (..)
SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline
BioTech 365
AUGUST 16, 2021
SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline Additional research reagents to detect mutations associated with delta variant of concern now available SYDNEY–(BUSINESS WIRE)–#COVID19–SpeeDx Pty.
Reagent 40
40 
The Native Antigen Company Launches Range of SARS-CoV-2 Specific Antibodies
BioTech 365
OCTOBER 7, 2020
Ten new monoclonal antibodies recognise distinct Spike protein epitopes on SARS-CoV-2 Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein Different epitopes support identification of matched-pair reagents for immunoassay development OXFORD, England–(BUSINESS WIRE)–The Native … (..)
Antibody 40
40 
Avacta Announces Collaboration Agreement With Bruker
The Pharma Data
JANUARY 27, 2021
Avacta has worked with Adeptrix Inc (Beverly, MA, USA) to develop a coronavirus antigen test that combines enrichment of the sample using Affimer® reagents with the analytical power of mass-spectrometry. Beverley, MA) (“Adeptrix”).
Reagent 52
52 
Let's personalize your content